CRBU:NASDAQ, Caribou Biosciences, Inc.

CRBU stock overview

Caribou Biosciences, Inc. (CRBU:NASDAQ) closed at $0.362 on November 13, 2026, down 4.81% on the day. The stock trades 85.5% below its 52-week high of $2.49 and 0.5% above its 52-week low of $0.360. Over the past year, it lost 80.9%. Caribou Biosciences, Inc. is part of the Health Care sector.

Key figures

Price: $0.362
Day change: -4.81%
Volume: 1,735,224
Average volume: 2,739,065
Market cap: 39M+
52-week range: $0.360 – $2.49
50-day average: $0.855
200-day average: $1.58

Price action over the past year

In 252 trading sessions since November 13, 2025, CRBU closed higher on 107 days (42%). Its best day was October 20, 2026 (+11.85%) and its worst was October 7, 2026 (-45.64%). The stock moved 10% or more in a single session 7 times. It opened at least 5% above the previous day's high 1 time.

Recent signals

Nov 14, 2026: Hit a new 52-Week Low of $0.362 (New Highs/Lows scanner)
Nov 6, 2026: News catalyst: Earnings (News Catalysts scanner)
Oct 7, 2026: Dropped 45.6% in a single session (Dips & Crashes scanner)

CRBU news

Nov 12, 2026: Caribou Biosciences (CRBU) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Nov 12, 2026: Caribou Biosciences (CRBU) Stock Sees Fair Value Cut After Clinical Programs Halted
Nov 6, 2026: Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Beats Revenue Estimates
Nov 5, 2026: Castle Biosciences, Inc. (CSTL) Reports Q3 Loss, Beats Revenue Estimates
Nov 5, 2026: Caribou Biosciences Reports Third Quarter 2026 Financial Results
Nov 5, 2026: Petrobras to Report Q3 Earnings: What's in the Cards for the Stock?
Nov 5, 2026: Agilent Technologies' Q4 Earnings on Deck: What's in Store for the Stock?
Nov 4, 2026: Caribou Biosciences, Inc. (CRBU) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

About Caribou Biosciences, Inc.

Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies.

Similar stocks

Find more stocks like CRBU with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.